A comprehensive approach to the prevention of bronchopulmonary dysplasia

Pediatric Pulmonology

Volumn 46, Issue 12, 2011, Pages 1153-1165

  Kugelman, Amir ^a   Durand, Manuel ^b  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

bronchopulmonary dysplasia; chronic lung disease of prematurity; nasal respiratory support; respiratory distress syndrome; surfactant; ventilatory strategies

Indexed keywords

ACETYLCYSTEINE; AZITHROMYCIN; BRONCHODILATING AGENT; CAFFEINE; CORTICOSTEROID; DEXAMETHASONE; DIURETIC AGENT; HYDROCORTISONE; INDOMETACIN; LUNG SURFACTANT; NITRIC OXIDE; PENTOXIFYLLINE; RETINOL; SUPEROXIDE DISMUTASE;

ARTICLE; ARTIFICIAL VENTILATION; ENDOTRACHEAL INTUBATION; HEMODYNAMIC PARAMETERS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERCAPNIA; INTERMITTENT POSITIVE PRESSURE VENTILATION; LOW DRUG DOSE; LUNG DYSPLASIA; NUTRITIONAL SUPPORT; OXYGENATION; PATENT DUCTUS ARTERIOSUS; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH PERFORATION; SURVIVAL RATE;

BRONCHOPULMONARY DYSPLASIA; CONTINUOUS POSITIVE AIRWAY PRESSURE; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INTUBATION, INTRATRACHEAL; POSTNATAL CARE; PREMATURE BIRTH; PRENATAL CARE; PULMONARY SURFACTANTS; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 81255127527     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21508     Document Type: Article

References (112)

1. Jobe AH, Bancalari E,. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723-1729. (Pubitemid 32578778)
2. Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A,. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol 2003; 23: 451-456. (Pubitemid 37258559)
3. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, Wrage LA, Poole K, National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116: 1353-1360. (Pubitemid 46056482)
4. Allen J, Zwerdling R, Ehrenkranz R, Gaultier C, Geggel R, Greenough A, Kleinman R, Klijanowicz A, Martinez F, Ozdemir A, Panitch HB, Nickerson B, Stein MT, Tomezsko J, Van Der Anker J, American Thoracic Society. Statement on the care of the child with chronic lung disease of infancy and childhood. Am J Respir Crit Care Med 2003; 168: 356-396.
5. Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR, Bauer CR, Donovan EF, Korones SB, Laptook AR, Lemons JA, Oh W, Papile LA, Shankaran S, Stevenson DK, Tyson JE, Poole WK, NICHD Neonatal Research Network. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196: 147.e1-147.e8.
6. Baraldi E, Filippone M,. Chronic lung disease after premature birth. N Engl J Med 2007; 357: 1946-1955. (Pubitemid 350074689)
7. Robin B, Kim YJ, Huth J, Klocksieben J, Torres M, Tepper RS, Castile RG, Solway J, Hershenson MB, Goldstein-Filbrun A,. Pulmonary function in bronchopulmonary dysplasia. Pediatr Pulmonol 2004; 37: 236-242. (Pubitemid 38326373)
8. Filbrun AG, Popova AP, Linn MJ, McIntosh NA, Hershenson MB,. Longitudinal measures of lung function in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 2011; 46: 369-375.
9. Hayes D Jr, Meadows JT Jr, Murphy BS, Feola DJ, Shook LA, Ballard HO,. Pulmonary function outcomes in bronchopulmonary dysplasia through childhood and into adulthood: implications for primary care. Prim Care Respir J 2011; 20: 128-133.
10. Jobe AH,. Antenatal factors and the development of bronchopulmonary dysplasia. Semin Neonatol 2003; 8: 9-17. (Pubitemid 36356489)
11. Speer CP,. Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med 2006; 11: 354-362. (Pubitemid 44038701)
12. Speer CP,. Chorioamnionitis, postnatal factors and proinflammatory response in the pathogenetic sequence of bronchopulmonary dysplasia. Neonatology 2009; 95: 353-361.
13. Van Marter LJ, Dammann O, Allred EN, Leviton A, Pagano M, Moore M, Martin C, Developmental Epidemiology Network Investigators. Chorioamnionitis, mechanical ventilation, and postnatal sepsis as modulators of chronic lung disease in preterm infants. J Pediatr 2002; 140: 171-176. (Pubitemid 34183655)
14. McEvoy C, Schilling D, Peters D, Tillotson C, Spitale P, Wallen L, Segel S, Bowling S, Gravett M, Durand M,. Respiratory compliance in preterm infants after a single rescue course of antenatal steroids: a randomized controlled trial. Am J Obstet Gynecol 2010; 202: 544.e1-544.e9.
15. Bader D, Kugelman A, Boyko V, Levitzki O, Lerner-Geva L, Riskin A, Reichman B, Israel Neonatal Network. Risk factors and estimation tool for death among extremely premature infants: a national study. Pediatrics 2010; 125: 696-703.
16. National Institutes of Health Consensus Development Conference Statement. Effect of corticosteroids for fetal maturation on perinatal outcomes, February 28-March 2, 1994. Am J Obstet Gynecol 1995; 173: 246-252.
17. Silvers KM, Gibson AT, Russell JM, Powers HJ,. Antioxidant activity, packed cell transfusions, and outcome in premature infants. Arch Dis Child Fetal Neonatal Ed 1998; 78: F214-F219. (Pubitemid 28240412)
18. Jobe AH,. Pulmonary surfactant therapy. N Engl J Med 1993; 328: 861-868. Review. (Pubitemid 23084342)
19. Ramanathan R,. Choosing a right surfactant for respiratory distress syndrome treatment. Neonatology 2009; 95: 1-5. Review.
20. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A, Poole WK, Schibler K, Newman NS, Ambalavanan N, Frantz ID, Piazza AJ, Sánchez PJ, Morris BH, Laroia N, Phelps DL, Poindexter BB, Cotten CM, Van Meurs KP, Duara S, Narendran V, Sood BG, O'Shea TM, Bell EF, Ehrenkranz RA, Watterberg KL, Higgins RD,. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010; 362: 1959-1969.
21. Claure N, Bancalari E, D'Ugard C, Nelin L, Stein M, Ramanathan R, Hernandez R, Donn SM, Becker M, Bachman T,. Multicenter crossover study of automated control of inspired oxygen in ventilated preterm infants. Pediatrics 2011; 127: e76-e83.
22. Ratner V, Slinko S, Utkina-Sosunova I, Starkov A, Polin RA, Ten VS,. Hypoxic stress exacerbates hyperoxia-induced lung injury in a neonatal mouse model of bronchopulmonary dysplasia. Neonatology 2009; 95: 299-305.
23. Mariani G, Cifuentes J, Carlo WA,. Randomized trial of permissive hypercapnia in preterm infants. Pediatrics 1999; 104: 1082-1088. (Pubitemid 29529183)
24. Thome UH, Carlo WA,. Permissive hypercapnia. Semin Neonatol 2002; 7: 409-419. (Pubitemid 35440226)
25. Hagen EW, Sadek-Badawi M, Carlton DP, Palta M,. Permissive hypercapnia and risk for brain injury and developmental impairment. Pediatrics 2008; 122: e583-e589.
26. Kaiser JR, Gauss CH, Pont MM, Williams DK,. Hypercapnia during the first 3 days of life is associated with severe intraventricular hemorrhage in very low birth weight infants. J Perinatol 2006; 26: 279-285.
27. Thome UH, Carroll W, Wu TJ, Johnson RB, Roane C, Young D, Carlo WA,. Outcome of extremely preterm infants randomized at birth to different PaCO2 targets during the first seven days of life. Biol Neonate 2006; 90: 218-225. (Pubitemid 44775192)
28. Bollen CW, Uiterwaal CS, van Vught AJ,. Meta-regression analysis of high-frequency ventilation vs conventional ventilation in infant respiratory distress syndrome. Intensive Care Med 2007; 33: 680-688. (Pubitemid 46474901)
29. Cools F, Askie LM, Offringa M, Asselin JM, Calvert SA, Courtney SE, Dani C, Durand DJ, Gerstmann DR, Henderson-Smart DJ, Marlow N, Peacock JL, Pillow JJ, Soll RF, Thome UH, Truffert P, Schreiber MD, Van Reempts P, Vendettuoli V, Vento G, PreVILIG Collaboration. Elective high-frequency oscillatory versus conventional ventilation in preterm infants: a systematic review and meta-analysis of individual patients' data. Lancet 2010; 375: 2082-2091.
30. Greenough A, Premkumar M, Patel D,. Ventilatory strategies for the extremely premature infant. Paediatr Anaesth 2008; 18: 371-377. (Pubitemid 351490475)
31. Wheeler K, Klingenberg C, McCallion N, Morley CJ, Davis PG,. Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev 2010; 11: CD003666.
32. Greenough A, Dimitriou G, Prendergast M, Milner AD,. Synchronized mechanical ventilation for respiratory support in newborn infants. Cochrane Database Syst Rev 2008; 1: CD000456.
33. Ramanathan R,. Optimal ventilatory strategies and surfactant to protect the preterm lungs. Neonatology 2008; 93: 302-308. (Pubitemid 351799114)
34. Hillman NH, Moss TJ, Kallapur SG, Bachurski C, Pillow JJ, Polglase GR, Nitsos I, Kramer BW, Jobe AH,. Brief, large tidal volume ventilation initiates lung injury and a systemic response in fetal sheep. Am J Respir Crit Care Med 2007; 176: 575-581. (Pubitemid 47403275)
35. Himpens E, Oostra A, Franki I, Vansteelandt S, Vanhaesebrouck P, den Broeck CV,. Predictability of cerebral palsy in a high-risk NICU population. Early Hum Dev 2010; 86: 413-417.
36. Van Marter LJ, Kuban KC, Allred E, Bose C, Dammann O, O'Shea M, Laughon M, Ehrenkranz RA, Schreiber MD, Karna P, Leviton A, ELGAN Study Investigators. Does bronchopulmonary dysplasia contribute to the occurrence of cerebral palsy among infants born before 28 weeks of gestation? Arch Dis Child Fetal Neonatal Ed 2011; 96: F20-F29.
37. Laptook AR, O'Shea TM, Shankaran S, Bhaskar B, NICHD Neonatal Network. Adverse neurodevelopmental outcomes among extremely low birth weight infants with a normal head ultrasound: prevalence and antecedents. Pediatrics 2005; 115: 673-680. (Pubitemid 43373028)
38. Aly H, Massaro AN, Patel K, El-Mohandes AA,. Is it safer to intubate premature infants in the delivery room? Pediatrics 2005; 115: 1660-1665. (Pubitemid 43843177)
39. Aly H, Milner JD, Patel K, El-Mohandes AA,. Does the experience with the use of nasal continuous positive airway pressure improve over time in extremely low birth weight infants? Pediatrics 2004; 114: 697-702. (Pubitemid 41529526)
40. Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, Carlin JB, COIN Trial Investigators. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008; 358: 700-708. Erratum in: N Engl J Med 2008; 358(14): 1529. (Pubitemid 351240749)
41. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A, Poole WK, Donovan EF, Newman NS, Ambalavanan N, Frantz ID, Buchter S, Sánchez PJ, Kennedy KA, Laroia N, Poindexter BB, Cotten CM, Van Meurs KP, Duara S, Narendran V, Sood BG, O'Shea TM, Bell EF, Bhandari V, Watterberg KL, Higgins RD,. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010; 362: 1970-1979. Erratum in: N Engl J Med 2010; 362(23): 2235.
42. Avery ME, Tooley WH, Keller JB, Hurd SS, Bryan MH, Cotton RB, Epstein MF, Fitzhardinge PM, Hansen CB, Hansen TN, Hodson WA, James LS, Kitterman JA, Nielsen HC, Poirier TA, Truog WE, Wung J-T,. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics 1987; 79: 26-30. (Pubitemid 17060953)
43. Van Marter LJ, Allred EN, Pagano M, Sanocka U, Parad R, Moore M, Susser M, Paneth N, Leviton A,. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics 2000; 105: 1194-1201. (Pubitemid 30346886)
44. Vanpée M, Walfridsson-Chultz U, Katz-Salamon M, Zupancic JA, Pursley D, Jõnsson B,. Resuscitation and ventilation strategies for extremely preterm infants: a comparison study between two neonatal centers in Boston and Stockholm. Acta Paediatr 2007; 96: 10-16.
45. Davis PG, Henderson-Smart DJ,. Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants (Review). Cochrane Database Syst Rev 2003; 2: CD000143.
46. Chang HY, Claure N, D'ugard C, Torres J, Nwajei P, Bancalari E,. Effects of synchronization during nasal ventilation in clinically stable preterm infants. Pediatr Res 2011; 69: 84-89.
47. Kugelman A, Feferkorn I, Riskin A, Chistyakov I, Kaufman B, Bader D,. Nasal intermittent mandatory ventilation versus nasal continuous positive airway pressure for respiratory distress syndrome: a randomized, controlled, prospective study. J Pediatr 2007; 150: 521-526, 526.e1.
48. Bisceglia M, Belcastro A, Poerio V, Raimondi F, Mesuraca L, Crugliano C, Corapi UP,. A comparison of nasal intermittent versus continuous positive pressure delivery for the treatment of moderate respiratory distress syndrome in preterm infants. Minerva Pediatr 2007; 59: 91-95. (Pubitemid 46975299)
49. Sai Sunil Kishore M, Dutta S, Kumar P,. Early nasal intermittent positive pressure ventilation versus continuous positive airway pressure for respiratory distress syndrome. Acta Paediatr 2009; 98: 1412-1415.
50. Meneses J, Bhandari V, Guilherme Alves J, Herrmann D,. Noninvasive ventilation for respiratory distress syndrome: a randomized controlled trial. Pediatrics 2011; 127: 300-307.
51. Barrington KJ, Bull D, Finer NN,. Randomized trial of nasal synchronized intermittent mandatory ventilation compared with continuous positive airway pressure after extubation of very low birth weight infants. Pediatrics 2001; 107: 638-641. (Pubitemid 32268444)
52. Khalaf MN, Brodsky N, Hurley J, Bhandari V,. A prospective randomized, controlled trial comparing synchronized nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure as modes of extubation. Pediatrics 2001; 108: 13-17. (Pubitemid 32591999)
53. Davis PG, Lemyre B, de Paoli AG,. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev 2001; 3: CD003212. Review.
54. Moretti C, Giannini L, Fassi C, Gizzi C, Papoff P, Colarizi P,. Nasal flow-synchronized intermittent positive pressure ventilation to facilitate weaning in very low-birthweight infants: unmasked randomized controlled trial. Pediatr Int 2008; 50: 85-91. (Pubitemid 351239405)
55. Kulkarni A, Ehrenkranz RA, Bhandari V,. Effect of introduction of synchronized nasal intermittent positive-pressure ventilation in a neonatal intensive care unit on bronchopulmonary dysplasia and growth in preterm infants. Am J Perinatol 2006; 23: 233-240.
56. Bhandari V, Finer NN, Ehrenkranz RA, Saha S, Das A, Walsh MC, Engle WA, VanMeurs KP, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Synchronized nasal intermittent positive-pressure ventilation and neonatal outcomes. Pediatrics 2009; 124: 517-526.
57. Bhandari V,. Nasal intermittent positive pressure ventilation in the newborn: review of literature and evidence-based guidelines. J Perinatol 2010; 30: 505-512.
58. Ramanathan R,. Nasal respiratory support through the nares: its time has come. J Perinatol 2010; 30: S67-S72.
59. Finer NN, Carlo WA, Duara S, Fanaroff AA, Donovan EF, Wright LL, Kandefer S, Poole WK, National Institute of Child Health and Human Development Neonatal Research Network. Delivery room continuous positive airway pressure/positive end-expiratory pressure in extremely low birth weight infants: a feasibility trial. Pediatrics 2004; 114: 651-657. (Pubitemid 41529520)
60. Stevens TP, Harrington EW, Blennow M, Soll RF,. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2007; 4: CD003063. Review.
61. Bhandari V, Gavino RG, Nedrelow JH, Pallela P, Salvador A, Ehrenkranz RA, Brodsky NL,. A randomized controlled trial of synchronized nasal intermittent positive pressure ventilation in RDS. J Perinatol 2007; 27: 697-703. (Pubitemid 350020350)
62. Ramanathan R, Sekar K, Rasmussen M, Bhatia J, Soll R,. Nasal intermittent mandatory ventilation (NIPPV) versus synchronized intermittent mandatory ventilation (SIMV) after surfactant treatment for respiratory distress syndrome (RDS) in preterm infants <30 weeks gestation: multicenter, randomized, clinical trial [abstract]. EPAS. 2009; 3213-3216. Available at:.
63. Thomas W, Speer CP,. Nonventilatory strategies for prevention and treatment of bronchopulmonary dysplasia-what is the evidence? Neonatology 2008; 94: 150-159.
64. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W, North American Recombinant Human CuZnSOD Study Group. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003; 111: 469-476. (Pubitemid 36330700)
65. Kribs A, Hartel C, Kattner E, Vochem M, Kuster H, Moller J, Muller D, Segerer H, Wieg C, Gebauer C, Nikischin W, Wense A, Herting E, Roth B, Gopel W,. Surfactant without intubation in preterm infants with respiratory distress: first multi-center data. Klin Paediatr 2010; 222: 13-17.
66. Dargaville PA, Aiyappan A, Cornelius A, Williams C, De Paoli AG,. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Arch Dis Child Fetal Neonatal Ed 2011; 96: F243-248.
67. Soll RF, Morley CJ,. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2001; 2: CD000510. Review.
68. Greenough A,. Emerging drugs for the prevention of bronchopulmonary dysplasia. Expert Opin Emerg Drugs 2008; 13: 537-546. Review.
69. Schmidt B, Roberts R, Millar D, Kirpalani H,. Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology 2008; 93: 284-287. (Pubitemid 351799111)
70. Darlow BA, Graham PJ,. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2007; 4: CD000501.
71. Abman SH,. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 2007; 91: 283-290. (Pubitemid 46934213)
72. Kinsella JP, Abman SH,. Inhaled nitric oxide in the premature newborn. J Pediatr 2007; 151: 10-15. (Pubitemid 46935169)
73. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, Perritt R, Higgins RD, Oh W, Hudak ML, Laptook AR, Shankaran S, Finer NN, Carlo WA, Kennedy KA, Fridriksson JH, Steinhorn RH, Sokol GM, Konduri GG, Aschner JL, Stoll BJ, D'Angio CT, Stevenson DK, Preemie Inhaled Nitric Oxide Study. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005; 353: 13-22. (Pubitemid 41007803)
74. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C, Sekar KC, Auten RL, Bhutani VK, Gerdes JS, George TN, Southgate WM, Carriedo H, Couser RJ, Mammel MC, Hall DC, Pappagallo M, Sardesai S, Strain JD, Baier M, Abman SH,. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006; 355: 354-364. (Pubitemid 44127538)
75. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, Walsh MC, Durand DJ, Mayock DE, Eichenwald EC, Null DR, Hudak ML, Puri AR, Golombek SG, Courtney SE, Stewart DL, Welty SE, Phibbs RH, Hibbs AM, Luan X, Wadlinger SR, Asselin JM, Coburn CE, NO CLD Study Group. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355: 343-353. Erratum in: N Engl J Med 2007; 357(14) 1444-1445. (Pubitemid 44127537)
76. Walsh MC, Hibbs AM, Martin CR, Cnaan A, Keller RL, Vittinghoff E, Martin RJ, Truog WE, Ballard PL, Zadell A, Wadlinger SR, Coburn CE, Ballard RA, NO CLD Study Group. Two-year neurodevelopmental outcomes of ventilated preterm infants treated with inhaled nitric oxide. J Pediatr 2010; 156: 556.e1-561.e1.
77. Mercier JC, Hummler H, Durrmeyer X, Sanchez-Luna M, Carnielli V, Field D, Greenough A, Van Overmeire B, Jonsson B, Hallman M, Baldassarre J, EUNO Study Group. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet 2010; 376: 346-354.
78. Barrington KJ, Finer NN,. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2007; 3: CD000509.
79. Barrington KJ, Finer NN,. Inhaled nitric oxide for preterm infants: a systematic review. Pediatrics 2007; 120: 1088-1099. Review. Erratum in: Pediatrics 2008; 121(2):451. (Pubitemid 350085545)
80. Cole FS, Alleyne C, Barks JDE, Boyle RJ, Carroll JL, Dokken D, Edwards WH, Georgieff M, Gregory K, Johnston MV, Kramer M, Mitchell C, Neu J, Pursley DM, Robinson WM, Rowitch DH,. NIH Consensus Development Conference Statement: inhaled nitric-oxide therapy for premature infants. Pediatrics 2011; 127: 363-369.
81. Donohue PK, Gilmore MM, Cristofalo E, Wilson RF, Weiner JZ, Lau BD, Robinson KA, Allen MC,. Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics 2011; 127: e414-e422.
82. Yoder BA, Harrison M, Clark RH,. Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics 2009; 124: 673-679.
83. Doyle LW, Ehrenkranz RA, Halliday HL,. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010; 98: 217-224.
84. Doyle LW, Ehrenkranz RA, Halliday HL,. Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010; 98: 289-296.
85. Durand M, Mendoza ME, Tantivit P, Kugelman A, McEvoy C,. A randomized trial of moderately early low-dose dexamethasone therapy in very low birth weight infants: dynamic pulmonary mechanics, oxygenation, and ventilation. Pediatrics 2002; 109: 262-268. (Pubitemid 34126867)
86. McEvoy C, Bowling S, Williamson K, McGaw P, Durand M,. Randomized, double-blinded trial of low dose dexamethasone: II. Functional residual capacity and pulmonary outcome in very low birth weight infants at risk for bronchopulmonary dysplasia. Pediatr Pulmonol 2004; 38: 55-63. (Pubitemid 38823758)
87. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB,. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006; 117: 75-83. (Pubitemid 46050522)
88. American Academy of Pediatrics, Committee on Fetus and Newborn. Policy statement-postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010; 126: 800-808.
89. Doyle LW, Ehrenkranz RA, Halliday HL,. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010; 98: 111-117.
90. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC,. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005; 115: 655-661. (Pubitemid 43373025)
91. Jobe AH,. Postnatal corticosteroids for bronchopulmonary dysplasia. Clin Perinatol 2009; 36: 177-188.
92. Pantalitschka T, Poets CF,. Inhaled drugs for the prevention and treatment of bronchopulmonary dysplasia. Pediatr Pulmonol 2006; 41: 703-708. (Pubitemid 44157352)
93. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W, Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354: 2112-2121. (Pubitemid 43736611)
94. Bancalari E,. Caffeine for apnea of prematurity. N Engl J Med 2006; 354: 2179-2181. (Pubitemid 43736619)
95. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W, Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007; 357: 1893-1902. (Pubitemid 350074685)
96. Farstad T, Bratlid D, Medbø S, Markestad T, The Norwegian Extreme Prematurity Study Group. Bronchopulmonary dysplasia-prevalence, severity and predictive factors in a national cohort of extremely premature infants. Acta Paediatr 2011; 100: 53-58.
97. Mosalli R, Alfaleh K,. Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in extremely low birth weight infants. Cochrane Database Syst Rev 2008; 1: CD006181.
98. Schmidt B, Roberts RS, Fanaroff A, Davis P, Kirpalani HM, Nwaesei C, Vincer M, TIPP Investigators. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr 2006; 148: 730-734.
99. Clyman R, Cassady G, Kirklin JK, Collins M, Philips JB III., The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Pediatr 2009; 154: 873-876.
100. Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A, Trial of Indomethacin Prophylaxis in Preterms Investigators. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr 2007; 150: 229-234, 234.e1.
101. Natarajan G, Chawla S, Aggarwal S,. Short-term outcomes of patent ductus arteriosus ligation in preterm neonates: reason for concern? Am J Perinatol 2010; 27: 431-437.
102. Stephens BE, Gargus RA, Walden RV, Mance M, Nye J, McKinley L, Tucker R, Vohr BR,. Fluid regimens in the first week of life may increase risk of patent ductus arteriosus in extremely low birth weight infants. J Perinatol 2008; 28: 123-128. (Pubitemid 351217639)
103. Bell EF, Acarregui MJ,. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2001; 3: CD000503.
104. Frank L, Sosenko IR,. Undernutrition as a major contributing factor in the pathogenesis of bronchopulmonary dysplasia. Am Rev Respir Dis 1988; 138: 725-729.
105. Radmacher PG, Rafail ST, Adamkin DH,. Nutrition and growth in VLBW infants with and without bronchopulmonary dysplasia. Neonatal Intensive Care 2004; 16: 22-26.
106. Bhatia J, Parish A,. Nutrition and the lung. Neonatology 2009; 95: 362-367.
107. Biniwale MA, Ehrenkranz RA,. The role of nutrition in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 2006; 30: 200-208. (Pubitemid 44062678)
108. Ehrenkranz RA, Dusick AM, Vohr BR, Wright LL, Wrage LA, Poole WK,. Growth in the neonatal intensive care unit influences neurodevelopmental and growth outcomes of extremely low birth weight infants. Pediatrics 2006; 117: 1253-1261. (Pubitemid 46071519)
109. Akram Khan M, Kuzma-O'Reilly B, Brodsky NL, Bhandari V,. Site-specific characteristics of infants developing bronchopulmonary dysplasia. J Perinatol 2006; 26: 428-435. (Pubitemid 43970953)
110. Oh W, Poindexter BB, Perritt R, Lemons JA, Bauer CR, Ehrenkranz RA, Stoll BJ, Poole K, Wright LL, Neonatal Research Network. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 2005; 147: 786-790. (Pubitemid 41774834)
111. Lai NM, Rajadurai SV, Tan KH,. Increased energy intake for preterm infants with (or developing) bronchopulmonary dysplasia/chronic lung disease. Cochrane Database Syst Rev 2006; 3: CD005093.
112. Friedlich P, Lecart C, Posen R, Ramicone E, Chan L, Ramanathan R,. A randomized trial of nasopharyngeal-synchronized intermittent mandatory ventilation versus nasopharyngeal continuous positive airway pressure in very low birth weight infants after infants after extubation. J Perinatol 1999; 19: 413-418.